KDR and neoplasm: First, apatinib selectively targets VEGFR-2, which binds to all the VEGF-A isoforms, VEGF-C, and VEGF-D to down-regulate VEGF-mediated endothelial cell proliferation, migration, and tumour microvascular density25,26.